iCBT for GD and Comorbidities - a Pilot
Launched by KAROLINSKA INSTITUTET · Oct 24, 2023
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "iCBT for GD and Comorbidities - a Pilot," is looking at a special type of online therapy called internet-based cognitive behavioral therapy (iCBT) designed for people dealing with gambling disorder (GD) and other related mental health conditions. The study will involve 30 participants aged 18 and older who are currently experiencing gambling issues and have been identified as having at least one other common mental health concern. Participants will go through the treatment and be assessed before, during, and after therapy, with follow-up evaluations three months later to see how effective the treatment has been.
To participate, individuals must have a gambling disorder confirmed by a specific test and must also be using a self-exclusion tool called "Spelpaus" for at least three months. They should not be receiving other psychological treatments for gambling at the same time and must not have severe depression or suicidal thoughts. This study is currently recruiting participants, and it offers a chance to receive support and therapy that could help improve their gambling behaviors and overall mental health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Screen positive for GD, as measured with the Gambling Disorder Identification Test (total score ≥20 GDIT).
- • Fulfilling GD, assessed according to the Structured Clinical Interview for Gambling Disorder (SCI-GD).
- • Utilization of "Spelpaus" (3 months from treatment start).
- • ≥18 years of age.
- • Able to provide digital informed consent.
- • Classified within pathways 2 or 3, as measured with the Gambling pathways Questionnaire (GPQ).
- • Screen positive for at least one common mental diagnosis in addition to GD, assessed according to the Web Screening Questionnaire (WSQ).
- Exclusion Criteria:
- • Other ongoing psychological treatment for GD.
- • Severe depression, screened according to the Montgomery Åsberg Depression Rating Scale (total score \>34 MADRS-S).
- • Suicidality, screening of ≥4 points on item 9 of the MADRS-S
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported